Clinical trial · Observational
Prevalence and Impact on QoL From Ototoxicity in Cancer Survivors
Identifying the Prevalence, Severity and the Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors: a Cross-sectional Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): due to COVID-19
Summary
Brief summary (as posted)
This study will involve collaborating with oncologists in the post-chemotherapy follow-up appointments. The participants who wish to consent to this study will then answer 3 short questionnaires (THI, HHIA and SF-36) about hearing loss, tinnitus and quality of life. The audiologist or the researcher, under the supervision of an audiologist, will then perform a simple, non-invasive hearing test on the participant. Should the participant have a hearing loss, they will be advise to seek help from their General Practitioner.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Chemotherapeutic Toxicity | — | UNRESOLVED | — |
| Hearing Loss, Sensorineural | — | UNRESOLVED | — |
| Tinnitus, Subjective | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| High frequency pure tone audiometry | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Quality of life questionnaire
- timeFrame
- Afer 6 months
- description
- Short form 36 item questionnaire to assess quality of life (0-100 scale, higher score means better outcome)
Secondary outcomes (3)
- measure
- Hearing loss
- timeFrame
- After 6 months
- description
- High frequency audiogram (PTA)
- measure
- Hearing Handicap Inventory for adults/elderly
- timeFrame
- After 6 months
- description
- Self reported hearing loss using the HHIA/HHIE questionnaire (0-100, higher score means more handicap)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Ability to give informed consent * Age 18+ at time of cancer diagnosis * At least 1 cycle of any type of platinum-based chemotherapy * 0-5 years following first cycle of platinum-based chemotherapy * Comprehensive understanding of the English language Exclusion Criteria: * Previous radiotherapy to the head and neck area * Pre-existing hearing deficits
References
Publications (0)
Data not yet available